

BURSTALL

September 12, 2019

VIA SEDAR

Alberta Securities Commission
British Columbia Securities Commission
Ontario Securities Commission

Dear Sirs/Mesdames:

**Re: InnoCan Pharma Corporation (the "Corporation") – Final Prospectus dated
September 12, 2019**

We refer to the final prospectus of the Corporation dated September 12, 2019 (the "**Prospectus**") relating to the distribution of a minimum of 5,055,556 units and a maximum of 6,111,112 units (the "**Offered Units**") of the Corporation at a price of \$0.18 per Offered Unit.

We consent to the use of our firm name on page 2 and under the heading "Experts" in the Prospectus.

We confirm that we have read the Prospectus and have no reason to believe that there are any misrepresentations in the information contained therein that are within our knowledge as a result of the services performed by us in connection with the preparation of the Prospectus.

This is a consent contemplated by section 10.1 of National Instrument 41-101 - *General Prospectus Requirements*, and to the extent permitted by law we disclaim any liability beyond the statutory liability provisions of Canadian securities legislation applicable to the Prospectus.

Yours truly,

BURSTALL LLP

(signed) "*Burstall LLP*"